Do you want to read an article? Please log in or register.
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
Inflammatory Bowel Disease
Related content
RECOMMENDED
Inflammatory Bowel Disease
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Gisbert JP, Chaparro M, Verstockt B, Kienle P, Minozzi S, Allocca M, Atreya R, Avellaneda N, Barreiro-de Acosta M, Battat R, Bettenworth D, Blumenstein I, Brown SR, Burke JP, Caprioli F, Casanova MJ, Christou N, de Buck van Overstraeten A, Doherty G, Eder P, El-Hussuna A, Ellul P, Fantini MC, Furfaro F, Greuter T, Hazel K, Holubar S, Kapizioni C, Kopylov U, Leong RW, Leventoglu S, Limdi JK, Noor NM, Papaconstantinou I, Peros G, Pouillon L, Reenaers C, Saibeni S, Schmidt C, Sousa P, Stassen LPS, Uzzan M, Vieujean S, Visser E, Myrelid P, Adamina M, Kucharzik T
doi: 10.1093/ecco-jcc/jjag066
Inflammatory Bowel Disease
Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial
J Crohns Colitis
Quraishi MN, Moakes CA, Yalchin M, Blackwell C, Segal J, Ives NJ, Magill L, Manzoor SE, Gerasimidis K, McMullan C, Mathers J, Horniblow R, Loi S, Kaur M, Loman NJ, Sharma N, Hawkey P, McCune V, Quick J, Nicholls S, McMurray C, Nichols B, Svolos V, Raguideau S, Kerbiriou C, Oo YH, Beggs AD, Crees N, Hansen R, Hart AL, Gaya DR, Quince C, Iqbal TH
doi: 10.1093/ecco-jcc/jjag006
Inflammatory Bowel DiseaseFurther Publications
Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry
United European Gastroenterol J
Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry
doi: 10.1002/ueg2.70141
Inflammatory Bowel Disease
Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry
Inflamm Bowel Dis
Guasch M, Calafat M, Gargallo-Puyuelo CJ, De Francisco R, Moraleja I, Vega P, de Castro L, Labarga F, Mesonero F, Castro-Poceiro J, Ponferrada-Díaz A, Brunet-Mas E, Sesé E, Ramos L, Quiñones M, Ruiz-Cerulla A, Castro B, Zabana Y, Iglesias E, Latras I, Varela P, Ricart E, Madero L, Elosua A, Vicente L, Lorente R, Betoré E, Roig C, Mañosa M, Domènech E, PERICO-ENEIDA Study of the GETECCU
doi: 10.1093/ibd/izag120
Inflammatory Bowel Disease
New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC
Clin Gastroenterol Hepatol
Raine T, Peyrin-Biroulet L, Begun J, Biedermann L, Blumenstein I, Cheifetz AS, Colombel JF, Dulai PS, Gecse KB, Jairath V, Nakase H, Panaccione R, Reinisch W, Verstockt B, Higgins PDR
doi: 10.1016/j.cgh.2026.07.011
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
Inflammatory Bowel Disease
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.
Inflamm Bowel Dis
Rubin DT, Schreiber S, Peyrin-Biroulet L, Danese S, Gianfrancesco MA, Soonasra A, Sidhu S, Vranic I, Shelbaya A, Gruben D, Wei Y, Winthrop KL, Curtis JR, Regueiro MD, Dubinsky MC
doi: 10.1093/ibd/izag142
Inflammatory Bowel Disease
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
Inflamm Bowel Dis
Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P
doi: 10.1093/ibd/izaf319
Inflammatory Bowel Disease
Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn's Disease and Ulcerative Colitis
Inflamm Bowel Dis
Gan X, Zhang Y, Zhang Y, Ye Z, Yang S, Xiang H, Huang Y, Wu Y, Zhang Y, Qin X
doi: 10.1093/ibd/izaf325